Back to today’s briefing

Story perspectives

U.S. Obesity Rate Drops as GLP-1 Medications Transform Health

3/15/2025

41 5

Summary

Obesity Rate Declines

For the first time in ten years, the U.S. obesity rate has declined, thanks to the rise of GLP-1 medications like Ozempic and Wegovy. These groundbreaking drugs are not just helping people shed pounds; they're also encouraging healthier eating habits, potentially transforming the food industry and slashing healthcare expenses in the process.

Summary

Medications Challenge Affordability

A recent study in JAMA Health Forum uncovers that while weight loss medications tirzepatide and semaglutide offer substantial health advantages, their steep prices hinder accessibility. For these drugs to become affordable for patients battling obesity in the U.S., costs need to plummet by 30% to 82%, highlighting a pressing issue in healthcare equity.

1 of 2

Obesity Rate Declines

For the first time in ten years, the U.S. obesity rate has declined, thanks to the rise of GLP-1 medications like Ozempic and Wegovy. These groundbreaking drugs are not just helping people shed pounds; they're also encouraging healthier eating habits, potentially transforming the food industry and slashing healthcare expenses in the process.

1 / 2